Contrast-enhanced three-dimensional power doppler angiography of the human prostate: correlation with biopsy outcome

Bogers, Hans A; Sedelaar, J.P. Michiel; Beerlage, Harrie P.; Rosette, Jean J.M.C.H. de la; Debruyne, F.M.J.; Wijkstra, Hessel; Aarnink, R.G.

doi:10.1016/s0090-4295(99)00040-0

Cited by 128 publications

(65 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Color and power Doppler were introduced to detect increased vascularity within the prostate that may correlate with prostate cancer [3,4,23,24]. More recently, microbubble-enhanced Doppler TRUS has shown improvement over unenhanced LoTRUS in identifying prostate cancer foci [25][26][27][28]. However, mixed reports on the utility of such technologies, and modest improvements demonstrated in cancer detection over unenhanced LoTRUS have limited their widespread adoption.…”

Section: Discussionmentioning

confidence: 99%

High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer

Pavlovich

Cornish

Mullins

et al. 2014

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Methods and materials: Twenty-five men with known prostate cancer scheduled for radical prostatectomy were preoperatively imaged with both LoTRUS (5 MHz) and HiTRUS (21 MHz). Dynamic cine loops and still images for each modality were saved and subjected to blinded review by a radiologist looking for hypoechoic foci ~5 mm in each sextant of the prostate. Following prostatectomy, areas of prostate cancer ~ 5 mm on pathologic review were anatomically correlated to LoTRUS and HiTRUS findings. The accuracy of LoTRUS and HiTRUS to visualize prostate cancer in each sextant of the prostate and to identify high-grade and locally advanced disease was assessed. The McNemar test was used to compare sensitivity and specificity and paired dichotomous outcomes between imaging modalities.Results: Among 69 sextants with pathologically identified cancerous foci at radical prostatecomy, HiTRUS visualized 45 and missed 24, whereas LoTRUS visualized 26 and missed 43. Compared with LoTRUS, HiTRUS demonstrated improved sensitivity (65.2% vs. 37.7%) and specificity (71.6% vs. 65.4%). HiTRUS's agreement with pathologic findings was twice as high as LoTRUS (P = 0.006). HiTRUS provided a nonsignificant increase in visualization of high-grade lesions (84% vs. 60%, P = 0.11).Conclusions: HiTRUS appears promising for prostate cancer imaging. Our initial experience suggests superiority to LoTRUS for the visualization of cancerous foci, and supports proceeding with a clinical trial in the biopsy setting.

show abstract

Section: Discussionmentioning

confidence: 99%

High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer

Pavlovich

Cornish

Mullins

et al. 2014

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

show abstract

“…Patel and Rickards, 9 based on the results of 274 biopsies, considered the CDU to be relatively useful in the diagnosis of neoplastic pathologies. Borges et al, 10 on the other hand, were the first to report on the use of Levovist s in 18 patients with suspected PCa, revealing a sensitivity of 85 against 77% for the TRUS; they quoted, in addition, six patients with normal TRUS and a positive contrast-enhancement in three of them (all these patients harbored a neoplasm). Recently, Halpern et al 11 have demonstrated that targeted biopsy performed on the basis of high-frequency color or Doppler findings will miss a substantial number of cancers detected with a modified sextant biopsy approach with laterally directed cores.…”

Section: Discussionmentioning

confidence: 99%

Does the adjunct of ecographic contrast medium Levovist® improve the detection rate of prostate cancer?

Pepe

Patanè

Panella

et al. 2003

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To evaluate whether the adjunct of an ultrasound contrast medium improves the detection rate of prostate cancer. Method: In 34 patients, scheduled to undergo a trans-perineal extended prostate biopsy, we carried out a color-Doppler ultrasound (CDU) of the prostate before and after i.v. injection of Levovist s , an ultrasound contrast medium. Further bioptic samples were taken in the areas where a marked increase in vascularization was noticed. Results: The overall diagnostic sensitivity, specificity and efficiency were respectively 72.7, 56.2 and 62.9% for transrectal ultrasound (TRUS); 80, 56.2 and 65.3% for CDU and 88.8, 54.5 and 68% for CDU after Levovist s injection; 66.5, 72.6 and 65.1% for digito-rectal examination (DRE); 100, 51.4 and 65.4% for total PSA; and 100, 88.8 and 94.3% for PSA free/total. In the 16 patients with prostate carcinoma, the sensitivity of CDU after Levovist s was 92.3, 66% for both DRE and TRUS, and 80% for DRE plus TRUS. Conclusions: Considering the cost and the results obtained (high sensitivity and low specificity), a routine use of Levovist s does not seem indicated in patients undergoing prostatic biopsy. An exception may be represented by patients with both negative DRE and TRUS.

show abstract

“…The extra reXectors of US signals in the blood Xow after the administration of microbubbles enhance the Doppler signal. The sensitivity of PDCEUS in biopsy controlled studies is reported between 65 and 93% [4,26,41,44]. However, speciWcity is still relatively low and clinical additional value is disputable [31].…”

Section: Dopplermentioning

confidence: 99%

Transrectal contrast enhanced ultrasound for diagnosis of prostate cancer

et al. 2007

View full text Add to dashboard Cite

Contrast-enhanced three-dimensional power doppler angiography of the human prostate: correlation with biopsy outcome

Cited by 128 publications

References 29 publications

High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer

High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer

Does the adjunct of ecographic contrast medium Levovist® improve the detection rate of prostate cancer?

Transrectal contrast enhanced ultrasound for diagnosis of prostate cancer

Contact Info

Product

Resources

About